CJC-1295 (no DAC) vs Sermorelin

CJC-1295 (no DAC)

A short-acting GHRH analogue. The GH pulse it produces is sharp, brief, and very close to what the pituitary does on its own. Stabilised against rapid breakdown, but without the albumin-binding modification that turns it into the long-acting DAC version.

Best for

Best when you want a more stable, longer-acting GHRH (especially the DAC version) and a stronger overall signal.

Sermorelin

The oldest GHRH analogue still in widespread use. The first 29 amino acids of natural GHRH, unmodified. Pulses the pituitary in line with the body's natural sleep-onset GH window.

Best for

Best when you want the shortest, most physiologic pulse and the longer real-world safety record.

CJC-1295 (no DAC)

The pulse-amplification pharmacology is well-characterised in short human studies. Teichman and colleagues (2006) is the canonical reference and the half-life and pulse-shape data is solid. What is missing is long-term outcome data in healthy adults. The chronic safety profile is reassuring by absence of major signals across two decades of grey-market use, but absence of signal is not the same as a chronic safety trial.

Sermorelin

Sermorelin held FDA approval for paediatric GH deficiency from 1997 to 2008, when it was withdrawn from the US market for commercial, not safety or efficacy, reasons. The paediatric trial base is real and was good enough to clear regulatory review. Adult body-recomposition and anti-aging use is off-label and supported by smaller open-label work and the on-label pharmacology rather than a dedicated RCT base in healthy adults. The chronic safety record is reassuring across 25+ years of clinical and grey-market use.